AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

ANTXAN2 Therapeutics2026-10-20 20:13 EST

AN2 Therapeutics to Participate at Upcoming Investor Conferences

SPROSpero Therapeutics2026-10-02 21:05 EST

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-09-03 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SCYXSCYNEXIS2026-08-25 23:06 EST

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SCYXSCYNEXIS2026-05-07 01:15 EST

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...